MX2022011464A - Tratamiento con epinefrina intranasal en polvo. - Google Patents

Tratamiento con epinefrina intranasal en polvo.

Info

Publication number
MX2022011464A
MX2022011464A MX2022011464A MX2022011464A MX2022011464A MX 2022011464 A MX2022011464 A MX 2022011464A MX 2022011464 A MX2022011464 A MX 2022011464A MX 2022011464 A MX2022011464 A MX 2022011464A MX 2022011464 A MX2022011464 A MX 2022011464A
Authority
MX
Mexico
Prior art keywords
powdered
treatment
intranasal epinephrine
dry powder
solid particles
Prior art date
Application number
MX2022011464A
Other languages
English (en)
Spanish (es)
Inventor
Galia Temtsin-Krayz
Pavel Kazhdan
Original Assignee
Nasus Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nasus Pharma Ltd filed Critical Nasus Pharma Ltd
Publication of MX2022011464A publication Critical patent/MX2022011464A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
MX2022011464A 2020-03-16 2021-03-16 Tratamiento con epinefrina intranasal en polvo. MX2022011464A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062989913P 2020-03-16 2020-03-16
US17/135,528 US11400045B2 (en) 2020-03-16 2020-12-28 Treatment with powdered intranasal epinephrine
PCT/IL2021/050288 WO2021186437A1 (en) 2020-03-16 2021-03-16 Treatment with powdered intranasal epinephrine

Publications (1)

Publication Number Publication Date
MX2022011464A true MX2022011464A (es) 2022-11-14

Family

ID=77664091

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011464A MX2022011464A (es) 2020-03-16 2021-03-16 Tratamiento con epinefrina intranasal en polvo.

Country Status (13)

Country Link
US (2) US11400045B2 (cg-RX-API-DMAC7.html)
EP (1) EP4121005A1 (cg-RX-API-DMAC7.html)
JP (2) JP2023517532A (cg-RX-API-DMAC7.html)
KR (1) KR20220154709A (cg-RX-API-DMAC7.html)
CN (1) CN115279340A (cg-RX-API-DMAC7.html)
AR (1) AR121593A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021239084A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022018440A2 (cg-RX-API-DMAC7.html)
CA (1) CA3175130A1 (cg-RX-API-DMAC7.html)
IL (1) IL296268A (cg-RX-API-DMAC7.html)
MX (1) MX2022011464A (cg-RX-API-DMAC7.html)
TW (1) TW202200119A (cg-RX-API-DMAC7.html)
WO (1) WO2021186437A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11400045B2 (en) * 2020-03-16 2022-08-02 Nasus Pharma Ltd. Treatment with powdered intranasal epinephrine
CN121265577A (zh) 2020-05-18 2026-01-06 奥瑞克索股份公司 用于药物递送的药物组合物
US12414916B2 (en) 2021-06-10 2025-09-16 Belhaven BioPharma Inc. Dry powder formulations of epinephrine and associated methods
US11617716B2 (en) 2021-06-10 2023-04-04 Belhaven BioPharma Inc. Dry powder formulations of epinephrine and associated methods
US12661315B2 (en) 2021-06-10 2026-06-23 Belhaven BioPharma Inc. Dry powder formulations of epinephrine and associated methods
TW202333658A (zh) 2021-11-25 2023-09-01 瑞典商奥瑞克索股份公司 包含腎上腺素之新穎醫藥組合物
GB202117016D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical device
AU2023322235A1 (en) * 2022-08-11 2025-03-13 De Motu Cordis Pty Ltd Inhalable epinephrine formulation
US12029709B2 (en) 2022-08-11 2024-07-09 De Motu Cordis Pty Ltd Inhalable epinephrine formulation
KR20260016535A (ko) * 2023-05-31 2026-02-03 오렉쏘 에이비 아드레날린 수용체 조절제를 포함하는 분무 건조 조성물
US20260108465A1 (en) 2024-10-21 2026-04-23 Belhaven BioPharma Inc. Compositions, devices, and methods for intranasal delivery of dry powder epinephrine

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR940006601A (ko) 1992-09-12 1994-04-25 야나가와 히로미 생리활성 펩티드 조성물
US6017963A (en) 1995-11-14 2000-01-25 Euro-Celtique, S.A. Formulation for intranasal administration
ATE289825T1 (de) 1999-04-21 2005-03-15 1355540 Ontario Inc Methacoline oder histamine formulierungen zur feststellung von asthma
GB2367756B (en) 2000-10-12 2003-01-08 Bespak Plc Dispensing apparatus
GB2380410B (en) 2001-10-05 2003-11-19 Alchemy Healthcare Ltd Apparatus for the nasal or oral delivery of a medicament
GB2384190A (en) 2002-01-22 2003-07-23 Bespak Plc Dispensing device for a powdered product
US20090246281A1 (en) 2003-11-03 2009-10-01 Norton Healthcare Ltd. Soft steroid compositions for use in dry powder inhalers
WO2006016530A1 (ja) 2004-08-10 2006-02-16 Translational Research, Ltd. 速効性でかつ高い吸収性を可能とする経鼻投与用組成物
GB0524194D0 (en) 2005-11-28 2006-01-04 Univ Aston Respirable powders
EP1960022A1 (en) 2005-11-29 2008-08-27 Alza Corporation Nasal delivery device for the delivery of a substance to the olfactory region
US20070178166A1 (en) 2005-12-15 2007-08-02 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
ES2652415T3 (es) * 2006-12-26 2018-02-02 Shin Nippon Biomedical Laboratories, Ltd. Preparación para aplicación transnasal
GB2448183A (en) 2007-04-05 2008-10-08 Optinose As Nasal powder delivery device
WO2009050726A2 (en) 2007-05-28 2009-04-23 Panacea Biotec Limited Compositions and methods for improved delivery of bupropion
RU2491067C2 (ru) 2007-08-06 2013-08-27 Байотай Терапис, Инк Способы лечения зависимости
US9101539B2 (en) 2009-05-15 2015-08-11 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
CN102166219B (zh) * 2010-05-25 2013-04-17 杭州天龙药业有限公司 一种鼻腔给药制剂及其应用
WO2012078804A1 (en) 2010-12-07 2012-06-14 Respira Therapeutics, Inc. Dry powder inhaler
US9949923B2 (en) 2011-03-15 2018-04-24 Optinose As Nasal delivery
US9789071B2 (en) 2012-06-27 2017-10-17 G2B Pharma, Inc. Intranasal formulation of epinephrine for the treatment of anaphylaxis
WO2014134070A1 (en) 2013-02-26 2014-09-04 Baxter International Inc. Treatment of central nervous system disorders by intranasal administration of immunoglobulin g
CN104274426A (zh) 2013-07-03 2015-01-14 陆克塞纳医药公司 昂丹司琼细粉、昂丹司琼气溶胶组合物及其用途
US20160220489A1 (en) 2013-09-03 2016-08-04 G2B Pharma Inc. Intranasal Formulation for the Treatment of Cardiopulmonary Resuscitation (CPR), Cardiac Life Support (CLS), Anaphylaxis and/or Anaphylactoid Reactions
CN105979999B (zh) 2013-12-11 2021-03-12 株式会社Jms 阳型连接器
AU2015228541B2 (en) 2014-03-14 2020-09-03 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
US20200069582A1 (en) 2014-07-03 2020-03-05 Darren Rubin Inhalable hemodynamic agents and methods of using the same
CN107205938A (zh) * 2014-12-18 2017-09-26 温德加普医疗股份有限公司 用于溶解或增溶治疗剂的方法和组合物
UA121874C2 (uk) 2015-02-17 2020-08-10 Елі Ліллі Енд Компані Порошкова назальна композиція для лікування гіпоглікемії
EP3842457A1 (en) 2015-09-09 2021-06-30 Novartis AG Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
CA3030359A1 (en) 2016-08-05 2018-02-08 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical powder compositions
CN110996912A (zh) * 2017-08-20 2020-04-10 福摩莱克斯医药创新有限公司 用于鼻内递送的干粉组合物
US11844859B2 (en) * 2017-08-20 2023-12-19 Nasus Pharma Ltd. Dry powder compositions for intranasal delivery
ES2791775B2 (es) * 2018-02-06 2023-01-20 Aegis Therapeutics Llc Formulaciones de epinefrina intranasal y metodos para el tratamiento de enfermedades
KR20200125632A (ko) * 2018-02-26 2020-11-04 신 니뽄 바이오메디칼 라보라토리즈, 엘티디. 분말 제제, 카트리지 및 디바이스
US11400045B2 (en) * 2020-03-16 2022-08-02 Nasus Pharma Ltd. Treatment with powdered intranasal epinephrine

Also Published As

Publication number Publication date
AU2021239084A1 (en) 2022-10-13
US12678402B2 (en) 2026-07-14
US11400045B2 (en) 2022-08-02
BR112022018440A2 (pt) 2022-11-01
US20230105615A1 (en) 2023-04-06
WO2021186437A1 (en) 2021-09-23
EP4121005A1 (en) 2023-01-25
TW202200119A (zh) 2022-01-01
AR121593A1 (es) 2022-06-22
CA3175130A1 (en) 2021-09-23
IL296268A (en) 2022-11-01
KR20220154709A (ko) 2022-11-22
JP2026094260A (ja) 2026-06-09
US20210283050A1 (en) 2021-09-16
CN115279340A (zh) 2022-11-01
JP2023517532A (ja) 2023-04-26

Similar Documents

Publication Publication Date Title
BR112022018440A2 (pt) Tratamento com epinefrina intranasal em pó
MX2021005764A (es) Composición farmacéutica que comprende inhibidores de poli (adenosina difosfato (adp)-ribosa) polimerasas (parp).
MX2022007086A (es) Agentes para la composicion oral.
PH12021550203A1 (en) Novel clove-containing aerosol-generating substrate
EP4696361A3 (en) Systems and methods for liquid injection
WO2018213576A8 (en) Self-righting articles
PH12021552049A1 (en) Novel aerosol-generating substrate
MX358592B (es) Método para formulación de fármaco basado en el aumento de la afinidad de superficies de micropartículas cristalinas hacia agentes activos.
WO2009029958A3 (en) Implantable delivery device
MX2007012228A (es) Dispositivo para dosificar y para nebulizacion en seco.
WO2018144771A3 (en) Tablet comprising abrasive for dental cleaning
MX389588B (es) Composiciones farmaceuticas nasales con un excipiente poroso.
TNSN05046A1 (en) Method of preparing dry powder inhalation compositions
EP4674271A3 (en) Encapsulation of high potency active agents
PH12022551468A1 (en) Compounds active towards nuclear receptors
MX2009008487A (es) Picoplatino encapsulado.
WO2006103407A3 (en) New pharmaceutical compositions useful in the treatment of migraine
WO2013104892A8 (en) Application of high dose compounds via inhalation
DE69925293D1 (de) Sprühbeschichtete mikropartikel für nadellose spritzen
MY203215A (en) Powdered coal supply device and toxic trace element elution suppression method
MX2019011136A (es) Proceso para elaborar tabletas con el uso de radiofrecuencia y particulas disipativas revestidas.
WO2020039264A3 (en) Chemotherapeutic pharmaceutical suspension for oral dosage
GEP20257802B (en) Delamanid-containing composition
TW200616611A (en) Stable particle formulations of erythropoietin receptor agonists
MX2025004084A (es) Uso de dosis mas altas de formulaciones de huperzina de liberacion modificada